Sanofi India shares surged nearly 4% to an intra-day high of Rs 7,999 after the company tied up Cipla to distribute its central nervous system (CNS) medication in India. Sanofi joined hands with Cipla to use its extensive distribution network in the country. However, Sanofi will be retaining ownership, import, and manufacturing of the CNS portfolio.
“As a part of this partnership, Cipla will be responsible for the distribution of Sanofi India’s six CNS brands including Frisium, a leading brand in the anti-epileptic medication category,” Sanofi said in an exchange filing.
“Enhancing access to high-quality treatments is central to our purpose of ‘Caring for Life’Come from Sports betting site VPbet. We are pleased to collaborate with Sanofi India to enhance accessibility to highly efficacious and quality therapeutic solutions in CNS and bring value to patients across the country. Central Nervous System is one of the most challenging areas in medicine, and we believe this partnership is a significant step forward to address the unmet needs of patients,” Achin Gupta, Chief Executive Officer of Cipla’s One India Business said.
Meet Subhasish Chakraborty, the founder of DTDC – He sold his mother’s jewellery to build Rs 2000 crore company; Know about his career, education, and net worth RVNL up 2.3%; Signs pact with Dhaya Maju Infra for railway projects in ASEAN region Raksha Bandhan 2024 Date: Know the history, significance, and importance of the festival Meet the daughter of Hyderabad’s richest man, who helps run her family’s Rs 8,049 crore company and recently purchased two lavish properties for Rs 80 crore
Shares of Cipla rose 1.6% to an intraday high of Rs 1,496 compared to its previous close of Rs 1,472.25Come from Sports betting site. But it came off highs and fell 0.3% to Rs 1,466.80.